儿童期与成年早期家族性高胆固醇血症筛查的成本效果研究
结果显示,筛查可减少心血管事件,但相对常规诊疗均不具成本效果;18岁筛查且LDL-C阈值≥190 mg/dL的ICER最低,为每获得1个QALY 289 700美元。
要点
- 儿童期或成年早期序贯FH筛查可减少心血管事件,但减少幅度小于总体人群的0.1%。
- 所有FH筛查策略相对常规诊疗均不具成本效果,最低ICER为每QALY 289 700美元。
- 若高筛查LDL-C结果后增加终生血脂监测和生活方式治疗,筛查可能变得具有成本效果。
核心结论
- 儿童期或成年早期序贯FH筛查可能有效,但相对常规诊疗不具成本效果。
- 在高度乐观的假设下,即高筛查LDL-C结果后增加生活方式治疗和终生血脂监测(包括非FH血脂异常患者),序贯FH筛查可能变得具有成本效果。
研究设计与样本
- 研究使用心血管疾病政策模型(CVD Policy Model),该模型是对国家健康与营养调查参与者心血管疾病危险因素管理和结局的经验证离散事件模拟。
- 模型输入包括国家数据源、临床试验、汇总纵向队列研究和已发表文献。
主要发现
- 模拟队列中,常规诊疗导致终生心血管事件总数为3 118 000例(95%不确定性区间:3 061 000-3 192 000),其中FH患者为16 182例(95%不确定性区间:15 683-16 827)。
- 儿童期FH筛查可避免1385至1820例心血管事件(总体人群减少<0.1%),成年早期FH筛查可避免1154至1448例心血管事件(减少<0.1%)。
- 所有FH筛查策略相对常规诊疗均不具成本效果;18岁筛查且LDL-C阈值≥190 mg/dL的ICER最低,为每获得1个QALY 289 700美元。
关键数值与推荐
- 序贯FH筛查策略包括儿童期(10岁)或成年早期(18岁)筛查,联合3个LDL-C阈值(≥130 mg/dL、≥160 mg/dL或≥190 mg/dL)以选择患者进行基因检测。
- ICER低于每QALY 100 000美元的策略被认为具有成本效果。
- 未来成本和QALY按每年3%贴现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Heterozygous familial hypercholesterolemia (FH), a genetic condition, results in lifelong increased low-density lipoprotein cholesterol (LDL-C) and increases lifetime cardiovascular disease (CVD) risk. Most individuals with FH remain undiagnosed, so early FH identification and treatment could lower CVD burden. OBJECTIVE: To evaluate the projected cost-effectiveness of population sequential FH screening (lipid testing followed by genetic testing after a high LDL-C measurement) at 10 or 18 years of age. DESIGN, SETTING, AND PARTICIPANTS: The CVD Policy Model, a validated discrete event simulation of CVD risk factor management and CVD outcomes in National Health and Nutrition Examination Survey participants, was used to simulate lifetime health and economic outcomes from a health care sector perspective for a hypothetical cohort of 4.2 million US 10-year-olds. Individual characteristics and health care processes informed CVD events (coronary heart disease or stroke) and survival probabilities. Model inputs included national data sources, clinical trials, pooled longitudinal cohort studies, and published literature. INTERVENTIONS: Usual care assumed only opportunistic lipid testing and LDL-C and CVD risk-guided treatment. When added to usual care, sequential FH screening strategies examined combinations of childhood (age 10 years) or early adulthood (age 18 years) screening with 3 LDL-C thresholds (≥130 mg/dL, ≥160 mg/dL, or ≥190 mg/dL) to select patients for genetic testing. MAIN OUTCOMES AND MEASURES: Primary outcomes were direct health care costs (2021 US dollars), quality-adjusted life-years (QALYs), and an incremental cost-effectiveness ratio (ICER). Future costs and QALYs were discounted 3% annually. Strategies with an ICER of less than $100 000 per QALY gained were considered cost-effective. RESULTS: For the simulated cohort, usual care would lead to 3 118 000 (95% uncertainty interval, 3 061 000-3 192 000) total lifetime CVD events, with 16 182 (95% uncertainty interval, 15 683-16 827) among those with FH. Childhood FH screening could avert between 1385 and 1820 CVD events (<0.1% reduction in overall population), and early adulthood FH screening could avert between 1154 and 1448 CVD events (<0.1% reduction). While effective, no FH screening strategies were cost-effective relative to usual care; screening at age 18 years using an LDL-C threshold of 190 mg/dL or greater had the lowest ICER, at $289 700 per QALY gained. Sequential FH screening could become cost-effective vs usual care if lifetime lipid monitoring plus lifestyle therapy increased after a high screening LDL-C result, including for patients with non-FH dyslipidemias. CONCLUSIONS AND RELEVANCE: Sequential FH screening in childhood or early adulthood could be effective but not cost-effective vs usual care. However, sequential FH screening could become cost-effective under highly optimistic assumptions about increased lifestyle therapy and increased lifetime lipid monitoring for patients with non-FH dyslipidemias.
引用
- Bellows BK, Zhang Y, Ruiz-Negrón N, et al. Familial Hypercholesterolemia Screening in Childhood and Early Adulthood: A Cost-Effectiveness Study. JAMA. 2026. PMID: 41206967. doi:10.1001/jama.2025.20648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。